Surrogate Endpoints Don't Convince ODAC: Panel Votes No On Two Centocor/Ortho Biotech Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
ODAC votes 14-1 against Yondelis in combination with Doxil for ovarian cancer, and 13-0 against Doxil in combination with docetaxel for metastatic breast cancer.
You may also be interested in...
Keeping Track: Four Novel Agents Clear FDA; Two Complete Response Letters Issued
The latest drug development news and highlights from our FDA Performance Tracker.
Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges
Risk mitigation in the oncology setting is unique, largely because of the different benefit/risk ratio, but also because the therapeutic area has "a de facto restricted distribution system," as FDA Office of Oncology Drug Products Director Richard Pazdur put it.
Oncology Has Different Risk Management Standards, FDA’s Pazdur Acknowledges
Risk mitigation in the oncology setting is unique, largely because of the different benefit/risk ratio, but also because the therapeutic area has "a de facto restricted distribution system," as FDA Office of Oncology Drug Products Director Richard Pazdur put it.